Bloomberg Intelligence Estée Lauder in Talks to Buy Puig to Create Beauty Giant
Mar 24, 2026
Clara Lizaraga, Madrid-based M&A reporter, explains Puig’s perfume and fashion brands and the family’s IPO motives. Sam Fazeli, biotech and industries analyst, touches on Pfizer’s Lyme vaccine trial and research funding concerns. Jennifer Rie, litigation analyst, outlines state-led legal challenges to media mergers and antitrust enforcement dynamics. Multiple short discussions cover strategic fit, regulatory risks, and market implications.
AI Snips
Chapters
Transcript
Episode notes
Puig Family Control Could Complicate Sale
- Puig remains family-controlled with over 90% of voting rights held by the founding family, complicating any deal that would cede control.
- Puig's recent IPO aimed to smooth succession, letting future generations keep ownership but step back from operational roles, so a sale would be notable.
Fashion Houses Fuel Puig's Fragrance Strength
- Puig's business pairs fashion houses (Carolina Herrera, Nina Ricci) with fragrance sales; the fashion image drives perfume demand, making the two hard to separate.
- Puig also owns niche luxury labels like Byredo and L'Artisan representing ~10–15% of revenue, attractive but limited growth levers.
Regulatory Risk Centers On Makeup Not Perfume
- Regulatory concerns are limited on fragrances but could arise on makeup overlap, since Puig owns Charlotte Tilbury, a top U.S. makeup brand.
- Antitrust scrutiny would likely focus on makeup market share rather than perfume businesses.